We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+44.75%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$89.5M
(+104%)
Cap. Flow
+$53.8M
Cap. Flow
% of AUM
30.68%
Top 10 Holdings %
Top 10 Hldgs %
49.35%
Holding
76
New
27
Increased
18
Reduced
14
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zymeworks
ZYME
|
+$13.2M |
| 2 |
Prothena Corp
PRTA
|
+$7.5M |
| 3 |
AstraZeneca
AZN
|
+$7.03M |
| 4 |
QuidelOrtho
QDEL
|
+$4.84M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$4.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRFS
Grifois
GRFS
|
+$7.79M |
| 2 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$6.86M |
| 3 |
ZYXI
Zynex
ZYXI
|
+$3.17M |
| 4 |
AGN
Allergan plc
AGN
|
+$2.59M |
| 5 |
UnitedHealth
UNH
|
+$1.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.33% |
| 2 | Real Estate | 0.86% |
| 3 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zymeworks
ZYME
$1.68B
| $15.2M | 8.65% |
420,836
+359,308
| +584% | +$13.2M |
|
|
EPIX
2
DELISTED
ESSA Pharma
EPIX
| $12.9M | 7.36% |
2,082,185
+1,764
| +0.1% | +$8.36K |
|
|
3
PUT
Zymeworks
ZYME
$1.68B
| $11.8M | 6.74% |
+327,900
| New | +$12.1M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.3M | 4.73% |
1,626,701
+19,548
| +1% | +$81.4K |
|
|
5
AstraZeneca
AZN
$263B
| $7.2M | 4.11% |
+68,107
| New | +$7.03M |
|
|
6
Prothena Corp
PRTA
$458M
| $7.06M | 4.02% |
+674,603
| New | +$7.5M |
|
|
7
QuidelOrtho
QDEL
$1.09B
| $6.91M | 3.94% |
+30,900
| New | +$4.84M |
|
|
EIGR
8
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $5.95M | 3.39% |
20,676
+7,169
| +53% | +$2.11M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.7M | 3.25% |
50,789
+2,989
| +6% | +$317K |
|
|
10
Sarepta Therapeutics
SRPT
$1.66B
| $5.53M | 3.15% |
+34,500
| New | +$4.69M |
|
11
iRadimed
IRMD
$1.21B
| $4.93M | 2.81% |
212,436
-22,374
| -10% | -$480K |
|
|
ADVM
12
DELISTED
Adverum Biotechnologies
ADVM
| $4.57M | 2.6% |
21,872
-9,518
| -30% | -$1.69M |
|
|
ZYXI
13
DELISTED
Zynex
ZYXI
| $4.39M | 2.5% |
194,195
-189,225
| -49% | -$3.17M |
|
|
IMMU
14
DELISTED
Immunomedics Inc
IMMU
| $4.22M | 2.4% |
+119,000
| New | +$3.48M |
|
15
DexCom
DXCM
$27.6B
| $3.87M | 2.21% |
38,200
-15,600
| -29% | -$1.4M |
|
16
Spyre Therapeutics
SYRE
$8.87B
| $3.42M | 1.95% |
14,794
-6,666
| -31% | -$1.27M |
|
17
Eli Lilly
LLY
$1.07T
| $3.41M | 1.95% |
+20,800
| New | +$3.19M |
|
18
NovoCure
NVCR
$2.04B
| $3.34M | 1.91% |
56,397
+50,800
| +908% | +$3.34M |
|
19
Vericel Corp
VCEL
$2.3B
| $3.3M | 1.88% |
238,532
-113,800
| -32% | -$1.54M |
|
|
NARI
20
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.19M | 1.82% |
+65,817
| New | +$3.14M |
|
21
Xenon Pharmaceuticals
XENE
$6.32B
| $3.15M | 1.79% |
250,897
+237,669
| +1,797% | +$3.02M |
|
22
AbbVie
ABBV
$458B
| $2.84M | 1.62% |
28,900
+2,400
| +9% | +$211K |
|
|
MSON
23
DELISTED
Misonix Inc
MSON
| $2.66M | 1.52% |
196,301
-42,032
| -18% | -$514K |
|
|
ITMR
24
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $2.61M | 1.49% |
140,524
+25,659
| +22% | +$404K |
|
25
OraSure Technologies
OSUR
$273M
| $2.6M | 1.48% |
+223,200
| New | +$2.9M |
|
Similar funds
TW
JC
M
SG
BW
BL
FFA
GWM
Soleus Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Soleus Capital Management held 76 positions worth $175M, up 104% from $85.9M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Soleus Capital Management deployed $53.8M of net new capital in Q2 2020, opening 27 new positions and adding to 18 existing holdings. Its largest new stake was Prothena Corp: 674,603 shares worth $7.06M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 98% a quarter earlier, followed by Real Estate and Communication Services.
On the sell side, the largest reduction was Harpoon Therapeutics, Inc. Common Stock, an estimated $6.86M trimmed.
- Soleus Capital Management's largest Q2 2020 buy was Prothena Corp: 674,603 shares worth $7.06M.
- Soleus Capital Management added most to Zymeworks in Q2 2020, an estimated $13.2M increase.
- Soleus Capital Management's biggest Q2 2020 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $6.86M.
- Soleus Capital Management fully exited Grifois in Q2 2020, selling an estimated $7.79M.
- Soleus Capital Management's ten largest holdings make up 49% of its $175M portfolio in Q2 2020.
- Soleus Capital Management opened 27 new positions and closed 15 in Q2 2020.
- Soleus Capital Management's portfolio value rose 104% quarter-over-quarter to $175M.
Based on Soleus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.